SXC Health Solutions (SXCI)
Q1 2012 Earnings Call
May 03, 2012 8:30 am ET
Mark A. Thierer - Chairman and Chief Executive Officer
Jeffrey Park - Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Finance
Bret D. Jones - Oppenheimer & Co. Inc., Research Division
Lawrence C. Marsh - Barclays Capital, Research Division
Andrew Schenker - Morgan Stanley, Research Division
George Hill - Citigroup Inc, Research Division
Brian Tanquilut - Jefferies & Company, Inc., Research Division
Brooks G. O'Neil - Dougherty & Company LLC, Research Division
Amanda Murphy - William Blair & Company L.L.C., Research Division
Robert M. Willoughby - BofA Merrill Lynch, Research Division
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the SXC Health Solutions 2012 First Quarter Results Conference Call. The company issued an earnings press release this morning, which has been filed with the SEC on Form 8-K and is also available on the Investor Information section of SXC's website at sxc.com. Listeners are reminded that portions of today's discussions contain forward-looking statements that reflect current views with respect to future events such as SXC's outlook for future performance and the closing of the pending Catalyst transaction. Any such statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those projected in the forward-looking statements. Please refer to the company's filings with the SEC for additional information on risk factors. We would also like to advise you that all forward-looking statements made on today's call are intended to fall within the Safe Harbor provisions of the Private Securities and Litigation Reform Act of 1995.
During the call, we will also discuss some items that do not conform to generally accepted accounting principles, including EBITDA and adjusted EPS. We have reconciled those items to the most comparable GAAP measures in the earnings release and in the Form 10-Q that will be filed with the SEC. Neither EBITDA nor adjusted EPS should be considered as an alternative to net income or cash flows from operating activities or any other performance or liquidity measure derived in accordance with GAAP.